A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
- Authors
- Park, Byeong-Bae; Kim, Won Seog; Suh, Cheolwon; Hong, Jung Yong; Yang, Deok-Hwan; Lee, Won Sik; Do, Young Rok; Koh, Young Il; Won, Jong-Ho; Kim, Min Kyoung; Jo, Jae-Cheol; Hyun, Shin Young; Kim, Jeong-A; Oh, Young Ha; Lee, Seung-Sook
- Issue Date
- Nov-2019
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Lymphoma and Hodgkin disease; neoplasia; salvage therapy; bendamustine
- Citation
- LEUKEMIA & LYMPHOMA, v.60, no.13, pp.3251 - 3257
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA & LYMPHOMA
- Volume
- 60
- Number
- 13
- Start Page
- 3251
- End Page
- 3257
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/11703
- DOI
- 10.1080/10428194.2019.1622100
- ISSN
- 1042-8194
- Abstract
- This trial was designed to investigate the efficacy and toxicity of bendamustine, carboplatin, and dexamethasone (BCD) for relapsed or refractory peripheral T-cell lymphomas (PTCLs), which would be expected to exhibit more promising clinical outcomes compared with bendamustine therapy alone. After treatments with BCD, eight patients exhibited a complete response (CR; 29%) and seven exhibited a partial response (PR; 25%). The overall response rate (ORR) was 54%. Five patients proceeded to ASCT and three patients finally achieved CR. The median progression-free survival (PFS) was 4.4 months (2.8-6.0, 95% CI). For a total of 85 cycles of BCD, grade 3 or 4 neutropenia, thrombocytopenia, and anemia occurred in 17.6, 38.8, and 16.5% of cycles, respectively. Only one patient experienced febrile neutropenia. BCD was a considerable salvage regimen for relapsed or refractory PTCLs with acceptable toxicity; AITL or ASCT eligible patients were more effective to BCD. ClinicalTrials.gov Identifier: NCT02424045
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 병리학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/11703)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.